The density and type of lymphocytes that infiltrate colon tumors are predictive of the clinical outcome of colon cancer. High densities of T helper 17 (T H 17) cells and inflammation predict poor outcome, whereas infiltration by T regulatory cells (T regs ) that naturally suppress inflammation is associated with longer patient survival. However, the role of T regs in cancer remains controversial. We recently reported that T regs in colon cancer patients can become proinflammatory and tumor-promoting. These properties were directly linked with their expression of RORgt (retinoic acid-related orphan receptor-gt), the signature transcription factor of T H 17 cells. We report that Wnt/ b-catenin signaling in T cells promotes expression of RORgt. Expression of b-catenin was elevated in T cells, including T regs , of patients with colon cancer. Genetically engineered activation of b-catenin in mouse T cells resulted in enhanced chromatin accessibility in the proximity of T cell factor-1 (Tcf-1) binding sites genome-wide, induced expression of T H 17 signature genes including RORgt, and promoted T H 17-mediated inflammation. Strikingly, the mice had inflammation of small intestine and colon and developed lesions indistinguishable from colitis-induced cancer. Activation of b-catenin only in T regs was sufficient to produce inflammation and initiate cancer. On the basis of these findings, we conclude that activation of Wnt/b-catenin signaling in effector T cells and/or T regs is causatively linked with the imprinting of proinflammatory properties and the promotion of colon cancer.
INTRODUCTION
The gastrointestinal tract is poised in a state of equilibrium that permits rapid protective responses against pathogens but curtails damage by hindering long-lasting vigorous inflammatory processes. This balance is achieved through interactions between proinflammatory T helper 17 (T H 17) cells and anti-inflammatory regulatory T cells (T regs ) (1) that suppress T H 17 inflammation in an interleukin-10 (IL-10)-dependent manner (2) (3) (4) (5) . Autoimmune disorders, in particular human inflammatory bowel disease (IBD), are etiologically associated with chronically deregulated inflammation (6, 7) . Both the progression of IBD to cancer (8) and the initiation and progression of sporadic colon cancer are driven by inflammation (9) (10) (11) (12) . Accordingly, infiltration of colon cancer tumors with T H 17 cells negatively correlates with patient survival (13) , whereas high densities of T regs predict better clinical outcomes (13) (14) (15) . The protective role of T regs in colon cancer is, however, controversial, and other reports suggest a negative correlation of high T reg densities with disease outcome (16) . We reported earlier that in human colon cancer, there is preferential expansion of a T reg subset that is potently T cell-suppressive but has T H 17 characteristics (11, 12, (17) (18) (19) . These T regs express the signature T H 17 transcription factor retinoic acid-related orphan receptor gt (RORgt) and promote inflammation and tumor growth (11, 12, 18) . Expression of RORgt by T cells, including T regs , is pivotal for sustaining pathologic inflammation in mouse polyposis, and genetic ablation of RORgt in these cells protects against polyposis (12, 17) . It is unclear what triggers up-regulation of RORgt in T cells in the course of polyposis and colon cancer. Elucidating the molecular mechanisms that shift the lymphocyte balance from anti-inflammatory to proinflammatory is expected to improve diagnosis and treatment of IBD and colon cancer.
Inactivation of the adenomatous polyposis coli (APC) gene is the initiating event in about 80% of human colon cancer cases (20) , inducing the development of aberrant crypt foci and polyps (21, 22) . Polyp growth is directly linked with stabilization of b-catenin (21, 22) , the central effector of the Wnt signaling pathway. Focal inflammatory reactions in response to the oncogenic event (22) and to the gut microbiota (23) also contribute to disease progression. In thymocytes, b-catenin is activated by T cell receptor (TCR) signaling, and together with its T cellspecific DNA binding partner T cell factor-1 (Tcf-1), b-catenin promotes thymic development and selection (24) (25) (26) (27) (28) (29) . The transgenic overexpression of b-catenin in thymocytes promotes expression of RORgt, which, in turn, controls the expression of prosurvival genes (30) . Accordingly, enhanced b-catenin activity is suggested to promote survival of ex vivogenerated mouse T regs (31) . By contrast, more recent findings suggest that pharmacologic activation of Wnt signaling suppresses Foxp3 and compromises the function of ex vivo-differentiated human T regs (32) . Furthermore, the ex vivo differentiation of T H 17 cells coincides with up-regulation of b-catenin and Wnt signaling genes (33) , and ablation of Tcf-1 promotes expression of IL-17 by T cells (34, 35) . These findings 1 are consistent with the notion that Wnt/b-catenin signaling promotes T H 17 differentiation.
Here, we evaluated the role of Wnt/b-catenin in dictating T cell functions in colitis and colon cancer and the pathogenic consequences thereof. We found that the expression of RORgt and gain of proinflammatory functions by T cells, including T regs , in colitis and colon cancer are regulated through b-catenin-mediated epigenetic reprogramming. Through the combined use of mouse models and patient specimens, we demonstrate the relevance of these findings to IBD and to colon cancer in humans. These findings provide a mechanism for the chronic shift in lymphocyte properties from antiinflammatory to proinflammatory and highlight the critical role of Wnt signaling within T cells in the epigenetic imprinting of inflammation in autoimmunity and cancer.
RESULTS
In human colitis and colon cancer, T cells express elevated levels of b-catenin Earlier, we provided evidence that b-catenin is activated downstream of the TCR (25) . Both IBD and colon cancer involve activation of T cells; therefore, we investigated whether the Wnt/b-catenin pathway was up-regulated in T cells in these diseases. We examined tissue and tumor sections from patients with long-standing ulcerative colitis (UC), UC-associated colon cancer, and sporadic colon cancer. Colitis and tumor samples were compared to control colon tissue from patients with arteriovenous malformation (AVM) or diverticular disease. The control specimens were selected on the basis of their noninflamed and noncancerous characteristics. Colonic tissues were sectioned and stained with specific antibodies to CD3 (T cells) and b-catenin, and expression of CD3 and b-catenin in the same cell was confirmed by immunofluorescence confocal microscopy.
We found that tumor tissues were enriched for T cells exhibiting strong membrane as well as cytoplasmic coexpression of b-catenin and CD3 (Fig. 1A and fig. S1 ). We quantified the frequencies of b-cateninexpressing T cells in UC-associated colon cancer specimens (Fig. 1A, a and b) , UC (Fig. 1A, c and d) , control uninflamed noncancerous colons (Fig. 1A , e and f), sporadic colon cancer tumors (Fig. 1A , g and h), and healthy margin of sporadic tumor cancers (Fig. 1A, i and j) . These analyses established that significantly more T cells infiltrated tumors (P < 0.0001) as compared to control and colitis tissue (P = 0.0062) (Fig. 1B , left panel, and table S1). A significantly increased fraction of infiltrating T cells in both colitis (P < 0.0001) and tumor tissue (P < 0.0001) expressed b-catenin compared to T cells in control colon or in the margins of tumors obtained from sporadic colon cancer patients (P = 0.0007) (Fig. 1B , right panel, and table S1). To further relate these changes within the tumor to systemic immunity, we determined the levels of b-catenin in lysates of purified CD4 + T cells and CD4 + CD25 + T regs from peripheral blood of colon cancer patients. Western blot analysis showed that T cells from cancer patients, including both T regs (P = 0.0023) and Fig. 1 . b-Catenin is up-regulated in T cells and T regs of colon cancer patients. (A) (Upper) Representative confocal images of CD3 (green), b-catenin (red), and DAPI (blue), or isotype controls rabbit immunoglobulin G (IgG) (green), mouse IgG1 (red), and DAPI (blue) immunofluorescence. Scale bars, 50 mm. CD3, b-catenin, and DAPI immunostaining is shown for UC-associated colon cancer (a), UC (c), control uninflamed and nonmalignant lesions from patients with AVM, or diverticular disease ("healthy") (e), sporadic colon cancer (g), and healthy margin of sporadic colon cancer (i). Immunostaining of the respective sections with isotype controls is shown in (b), (d), (f), (h), and (j). Arrowheads show CD3
+ b-catenin + T cells (also shown in inset images, which are three times enlarged), and arrows depict CD3 
CD3
+ T cells in stained sections as in (A). Quantified were control (healthy) AVM and diverticular disease patients (n = 7), UC patients (n = 5), UC colon cancer tumors (n = 7), healthy margin of sporadic colon cancer (n = 3), and sporadic colon cancer tumors (n = 4). Four to six independent fields per patient were quantified. Two-tailed t test statistics: CD3 + healthy/UC colon cancer (***P < 0.0001), UC/UC colon cancer (**P = 0.0062). %b-Catenin + among CD3 + healthy/UC (***P < 0.0001), healthy/UC colon cancer (***P < 0.0001), healthy margin/colon cancer (***P = 0.0007). (C) Western blot analysis of purified CD4 +
Foxp3
− and CD4
+

Foxp3
+ T cells from colon cancer patients (n = 10 and 7, respectively) and healthy donors (n = 7 and 6, respectively) normalized for b-tubulin. Western blots for representative patients are shown on the left, and graphs of all patients' cells are shown on the right. Each dot represents one patient. Two-tailed MannWhitney test: ***P = 0.0004 (CD4 (22, 36, 37) . Polyp-ridden mice at 3 months of age had increased frequencies of activated T cells in both spleen (50% activated versus 10% in healthy animals) and intestine (80% activated versus 50% in healthy animals) (Fig. 2, A To determine how the tumor microenvironment affected gene expression, mRNA was prepared from CD4 +
Foxp3GFP
− T cells and CD4
+
Foxp3GFP
+ T regs sorted to~97% purity and interrogated by ImmGen using Affymetrix arrays (12) . Expression of Wnt pathway genes was compared between polyp-ridden APC +/D468 and wild-type mice by Gene Set Enrichment Analysis (GSEA; Massachusetts Institute of Technology) using a Wnt pathway gene set (KEGG_WNT_SIGNALING_PATHWAY). This analysis revealed significant (P < 0.001) enrichment in the expression of Wnt pathway genes in CD4 + T cells infiltrating the intestine of APC +/D468 mice (Fig. 2 , E and F). A weaker but significant (P = 0.02) enrichment of Wnt pathway genes was detected in T regs infiltrating the intestinal tumors ( fig. S2C ). Multiple genes associated with the T H 17 lineage, including IL-17 and RORgt, were also up-regulated in T cells infiltrating the wild-type intestine. Expression of most of these genes increased further during polyposis (Fig. 2G ). These findings are in line with an earlier report that Wnt pathway genes are up-regulated during ex vivo T H 17 commitment (33) and with our earlier findings that RORgt + T cells are more frequent in the intestine of polyp-ridden APC +/D468 (12) and Ts4CreAPC +/lox468 mice (37) . Together, these observations connect Wnt/b-catenin signaling with the gain of T H 17 characteristics by T cells and T regs during polyposis.
Activation of b-catenin in T cells predisposes mice to intestinal inflammation, colitis, and cancer To understand the biological outcome of b-catenin expression in T cells, we activated b-catenin specifically in T cells using compound mutant CD4Cre (40) Ctnnb1 ex3 (21) mice or in T regs using Foxp3Cre (5) Ctnnb1 ex3 (21) mice. The Cre-mediated excision of b-catenin exon 3 removes phosphorylation sites that target the protein for degradation, thereby producing stable, dominant, constitutively active b-catenin. Both mouse models developed intestinal and colonic inflammation and polyps but with different kinetics and severity. The CD4CreCtnnb1 ex3 compound mutant progeny developed cachexia and rectal prolapse as early as 8 to 10 weeks of age. The Foxp3CreCtnnb1 ex3 progeny were healthy until 4 months but then also developed inflammation and polyps. In both instances, the penetrance was 100% with all mice developing disease.
Histologic analysis revealed crypt elongation in the colon and crypt and villus elongation in the small intestine of CD4CreCtnnb1 ex3 mice compared to littermate CD4Cre controls (Fig. 3A) . Accordingly, starting at 6 weeks of age, epithelial cells in both the small intestine and colon of CD4CreCtnnb1 ex3 mice showed increased mitotic activity (Fig. 3 , B and C, and table S1). By 8 to 10 weeks of age, CD4CreCtnnb1 ex3 mice began to develop active small intestine inflammation and chronic colitis. We observed progressive leukocyte infiltration that promoted ulcers and crypt distortion (Fig. 3D , a and b), granulomas (Fig. 3D , c), and crypt abscesses (Fig. 3D, d ). Ulcers together with dysplasia and focal invasion were also observed ( fig. S4, A and B) . In many of these lesions, the crypt epithelial cells had peripheral localization of b-catenin (fig. S4, C and D), suggesting that the invasion of crypts into the submucosa was a reaction to the formation of ulcers rather than cancer. By 4 to 8 months of age, more than half of the mice (7 of 13 mice) had developed from one to three adenomatous polyps, which were identified morphologically and by nuclear b-catenin staining (fig. S4, E and F). Polyps were concentrated in the distal ileum and proximal colon close to the cecum ( fig. S5 ). Small intestine polyps were histologically indistinguishable from those detected in mouse models of hereditary polyposis, which we have characterized in detail in our earlier studies (22, 36, 37) (Fig. 3 , E and F), whereas colonic polyps had a serrated architecture that is typical of more aggressive adenomatous polyps (40, 41) (Fig. 3G) .
Analysis of Foxp3CreCtnnb1 ex3 compound mutant mice revealed that Wnt/ b-catenin signaling in T regs critically contributed to colitis and cancer. Foxp3-CreCtnnb1 ex3 mice showed progressive inflammation leading to polyp formation. At 4 months, the mice had growing lymphoid structures in the small intestine ( fig. S6, A and B) . By 6 months of age, the follicles had become abnormally enlarged, covered by crypt and villus structures ( fig. S6, C and D) . Abnormally enlarged lymphoid follicles were also apparent in the colon ( fig. S6, E and F) . Nine-month-old mice had typical adenomatous polyps (Fig. 3H) consisting of aberrant epithelial cells with abnormal hyperchromatic nuclei (Fig. 3I) . In addition, hyperproliferative crypts were also seen, at times growing over enlarged lymphoid follicles (Fig. 3J) . Thus, sustained b-catenin activity in the T cell compartment causes inflammation, ulcers, and ultimately epithelial transformation and polyposis in the small intestine and colon.
Polyps in the small intestine and colon were densely infiltrated with mast cells, which localized to the parenchyma, stroma, and submucosa of the lesions (fig. S7, A and B) . Mastocytosis was focal, and mast cell numbers declined outside the polyps ( fig. S7C ). CD11b + myeloid cells, B220 + B cells, and CD11c + antigen-presenting cells were increased in numbers in the spleen and lymph nodes of the mice, indicating both local and systemic inflammation ( fig. S7D ).
Constitutive activation of b-catenin in T cells promotes T H 17 commitment and sustained inflammation
To confirm that gut pathologies were induced by constitutive activation of b-catenin in T cells rather than by leaky expression of Cre in gut epithelial cells, we depleted T cells and B cells by introducing a homozygous Rag2 mutation in CD4CreCtnnb1 ex3 mice. CD4CreCtnnb1 ex3 Rag2 −/− mice (n = 10) observed until 10 months of age did not exhibit inflammation or polyps (Fig. 4A) , demonstrating that progressive colitis and growth of polyps in CD4CreCtnnb1 ex3 mice were strictly lymphocyte-dependent. Additionally, intracellular b-catenin staining and fluorescence-activated cell sorting analysis of leukocytes derived from CD4CreCtnnb1 ex3 mice revealed that b-catenin protein levels were elevated in circulating CD4 and CD8 T cells but not in macrophages, dendritic cells, or B cells (Fig. 4B) . Stabilization of b-catenin was confirmed by Western blot analysis of sorted CD4 + T cells, which showed elevated expression of b-catenin in CD4 + T cells from the spleen and small intestine (Fig. 4C) .
To investigate the mechanism of action of b-catenin in T cells, we determined their activation status and numbers. T cells with constitutively active b-catenin expressed several activation markers including CD69, CD122, and NKG2D, and they down-regulated CD62L (Fig.  4D) . We reported earlier that stabilization of b-catenin during thymic development stalls differentiation of T cells at the double-positive stage (25, 26) . Accordingly, at 4 weeks of age, CD4CreCtnnb1 ex3 mice had fewer thymic and peripheral CD4 + and CD8 + T cells; however, by 8 weeks of age, the absolute numbers of peripheral T cells had increased to near-normal levels ( Fig. 4E and table S1 ).
An abnormally large fraction of CD4 + T cells from CD4CreCtnnb1 ex3 mice expressed IL-17 in the thymus and in peripheral lymphoid organs, including mesenteric lymph nodes and intestine (Fig. 5, A and B, and table S1). Furthermore, the proinflammatory cytokines IL-17, tumor necrosis factor-a (TNF-a), and IL-6 were elevated in the small intestine and cecum of CD4CreCtnnb1 ex3 mice ( Fig. 5C and table S1 ). To demonstrate their proinflammatory properties, we transferred total peripheral T cells (10 6 cells per mouse) from CD4CreCtnnb1 ex3 or control CD4Cre mice to Rag2 −/− recipients. Three weeks after transfer, T H 17 and T H 1 cytokines, as well as IL-10, but not IL-2, were significantly higher in the serum of mice that received T cells with constitutively active b-catenin as compared to mice that received control T cells (Fig. 5D and table S1 ). Mice receiving CD4CreCtnnb1 ex3 T cells did not survive beyond 4 weeks after transfer, whereas those receiving CD4Cre T cells remained healthy. These observations demonstrate that T cells with elevated levels of b-catenin are T H 17-biased and proinflammatory. This is in line with an earlier report that b-catenin is up-regulated in ex vivo-differentiated T H 17 cells (33) . On the basis of these observations, we conclude that high levels of b-catenin in T cells cause chronic T cell activation, T H 17 commitment, and pathogenic inflammation that predispose the small intestine and colon to cancer.
Activation of b-catenin impairs normal T reg development and function
Expression of b-catenin enhances survival of ex vivo-differentiated T regs (31) , raising the possibility that constitutive activation of b-catenin may lead to expansion of T regs . We observed that CD4CreCtnnb1 ex3 mice had reduced numbers of thymic Foxp3 + CD4
+ T regs compared to controls ( Fig. 6A and table S1 ). However, a T reg reduction was not apparent in spleen and lymph nodes (Fig. 6A and table S1 ), suggesting a developmental defect that is compensated in the periphery, perhaps through generation and/or survival of extrathymic T regs . To confirm that the defect was cell-intrinsic, we generated competitive bone marrow (BM) chimeras in which BM progenitors from CD4CreCtnnb1 ex3 (Thy1.2) and wild-type (Thy1.1) mice mixed at 1:1 ratio were injected into lethally irradiated syngeneic wild-type hosts. At 6 weeks after transfer, CD4CreCtnnb1 ex3 BM progenitors gave rise to significantly (P < 0.001) fewer thymic T regs than did wild-type BM progenitors ( fig.  S8 ). Therefore, we conclude that a cell-intrinsic defect accounts for the reduced generation of thymic T regs in CD4CreCtnnb1 ex3 mice.
Normally, T regs have potent anti-inflammatory properties. Adoptive transfer of T regs from healthy mice to lymphopenic mice suppresses the cytokine storm caused by previous or simultaneous transfer of naïve CD4 T cells (42) . The ability of T regs to suppress inflammation is protective, and adoptive T reg transfer into polyp-ridden mice suppresses cancer-associated inflammation and causes regression of the polyps (18) . However, we previously showed that T regs from mice with polyposis (18) or from colon cancer patients are functionally altered (11, 12) , exhibit T H 17 characteristics, and promote inflammation and tumor growth. Therefore, we considered that T regs with stabilized b-catenin may have lost their anti-inflammatory functions, and that this impairment is an underlying mechanism in colitis and colon cancer.
To ) to suppress the colitis. T regs with constitutively active b-catenin were significantly (P < 0.0001) less effective than control (CD4Cre) T regs in protecting the recipient mice from colitis (Fig. 6, B −/− recipients at the end point showed that a much larger fraction of the transferred T regs with constitutively active b-catenin expressed proinflammatory cytokines including IL-17, IFN-g, and TNF-a as compared to transferred wild-type T regs (Fig. 6, D and E) . T regs are also potent suppressors of T cell functions, which normally are assayed by their ability to suppress proliferation of stimulated CD4 + T cells in vitro. Foxp3 + T regs with constitutively active b-catenin inhibited proliferation of CD4 + T cells, although with less potency than control CD4Cre T regs (Fig. 6F ). These observations demonstrate that activation of b-catenin in T regs impairs their anti-inflammatory functions and contributes to systemic inflammation, colitis, and polyposis in CD4CreCtnnb1 ex3 mice.
b-Catenin increases chromatin accessibility and expression of target genes
We gained insight into the molecular mechanisms by which b-catenin alters the properties of T cells, by comparing gene expression of CD4CreCtnnb1 ex3 and wild-type thymocytes using Affymetrix arrays (26) . T cell-specific activation of b-catenin resulted in robust expression of T H 17 family genes including RORgt, the signature transcription factor of the T H 17 lineage (Fig. 7A ). This expression pattern showed a clear overlap with that of T cells from polyp-ridden APC +/D468 mice (Fig. 2G) . To investigate the underlying reason for the change in gene expression, we performed ChIP-seq analyses of Tcf-1 and the distribution of histone marks. In wild-type thymocytes, Tcf-1 preferentially bound to consensus TCF motifs (P < 10 ) within enhancers and promoters, and associated genome-wide with marks of open chromatin such as lysine acetylation of histone 3 (H3KAc) (Fig. 7B, upper panels, black lines) . In contrast, there was little association of Tcf-1 with marks of closed chromatin such as lysine 27 trimethylation of histone 3 (H3K27me3) (Fig. 7B , lower panels, black lines). Stabilization of b-catenin in CD4CreCtnnb1 ex3 thymocytes enhanced H3KAc marks in both promoters and enhancers spanning more than 3 kb from the Tcf-1 binding sites (Fig. 7B, upper  panels, red lines) . Conversely, H3K27me3 marks (Fig. 7B , lower panels, red lines) were reduced. These observations are consistent with the notion that the observed activation of gene expression involves interaction of b-catenin with its T cell-specific DNA binding partner Tcf-1. Presumably, Tcf-1 binds accessible loci, and b-catenin enhances their accessibility. Therefore, we tested the possibility that enhanced accessibility could translate into elevated gene expression.
Given that RORgt is the signature transcription factor for T H 17 differentiation and was found by our expression arrays to be up-regulated in CD4CreCtnnb1 ex3 thymocytes, we examined the epigenetic state of the Rorc locus, which encodes RORgt. Our ChIP-seq analysis revealed comparable Tcf-1 binding to bona fide promoter and intragenic regions of the RORgt gene in wild-type and CD4CreCtnnb1 ex3 thymocytes (Fig.  7C) . Marks of open chromatin such as H3KAc were significantly elevated in Tcf-1 bound regions (Fig. 7C) , covering a large part of the Rorc locus. This finding is in line with earlier findings that b-catenin induces histone acetylation by recruiting the histone acetyltransferases (HATs), CBP (cyclic adenosine monophosphate response element-binding protein), and p300 to Tcf sites (43) .
We confirmed the up-regulation of RORgt expression in T cells that had constitutively activated b-catenin using a transgenic RORgt reporter, by intracellular staining of RORgt and by reverse transcription polymerase chain reaction (PCR). We crossed reporter mice that contained an insertion of the GFP (G) gene in the RORgt locus (44) with CD4CreCtnnb1 ex3 and CD4Cre control mice. The resulting heterozygous RORgt G/+ mice had one wild-type (+) and one truncated (G) RORgt allele, but were healthy with no detectable hematopoietic abnormalities or other pathologies. RORgt is required during thymic development, but its expression is shut down in mature CD4 + single-positive (SP) thymocytes. Accordingly, the RORgt-GFP reporter was no longer expressed in control CD4Cre CD4 + SP. However, expression of RORgt-GFP was detectable in CD4CreCtnnb1 ex3 CD4 + SP that had stabilized b-catenin (Fig. 7D and table S1 ). A significantly larger fraction of peripheral CD4
+
Foxp3
− T cells (P = 0.0148) and CD4 + Foxp3 + T regs (P = 0.0076) in CD4CreCtnnb1 ex3 mice exhibited RORgt expression compared to the same cells in control CD4Cre mice (Fig. 7E and table S1 ). CD4CreRORgt G/G and CD4CreCtnnb1 ex3 RORgt G/G RORgt-deficient mice were used as intracellular staining controls. Consistently, quantitative PCR showed that RORgt expression was about fourfold higher in thymic and threefold higher in peripheral T regs with stabilized b-catenin (Fig. 7E, table S1 , and fig. S10 ). Thus, three independent assays showed increased expression of RORgt in thymocytes and T cells that had constitutively active b-catenin.
These findings demonstrate that activation of b-catenin in T cells introduces global changes in chromatin landscape, increases accessibility, and enhances expression of target genes including RORgt.
RORgt functions downstream of b-catenin compromise T reg properties
RORgt is the signature transcription factor of proinflammatory T H 17 cells, raising the possibility that T cell abnormalities upon constitutive activation of b-catenin are, in part, caused by deregulated expression of RORgt. Therefore, we analyzed CD4CreCtnnb1 ex3 RORgt G/G mice. In the absence of RORgt, normal development and function of T cells and T regs were partially restored despite the presence of constitutively active b-catenin. In particular, ablation of RORgt reduced the frequencies of IL-17-expressing peripheral CD4 + T cells and T regs to levels comparable to wild type ( Fig. 8A and table S1 ). This confirmed that RORgt was indispensable for the deregulation of T H 17 inflammation by b-catenin. Ablation of RORgt also increased the frequency of thymic T regs expressing the T reg markers Foxp3 and GITR (Fig. 8B and table S1 ). It further restored the expression of Foxp3 protein, which was reduced in T regs with activated b-catenin, to normal levels (Fig. 8, C and D, and table S1). Ablation of RORgt in CD4CreCtnnb1 ex3 T regs with constitutively active b-catenin significantly improved their ability to suppress proliferation of in vitro-activated T cells (P < 0.0001) (Fig. 8E and table  S1 ). These findings are consistent with the interpretation that T reg dysfunction in CD4CreCtnnb1 ex3 mice is the result of persistent b-catenin activity and activation of RORgt.
DISCUSSION
We recently reported that in human colon cancer, a subset of T regs that coexpress Foxp3 and RORgt expand preferentially in a tumor-dependent manner (12) . RORgt is the signature transcription factor of T H 17 cells and promotes expression of the proinflammatory cytokine IL-17 (45) . Here, we observed that expression of bcatenin was increasingly elevated in coloninfiltrating CD4
+ T cells, including T regs of patients with colon cancer and patients with long-lasting UC, as the chronically inflamed tissues progressed to cancer. These findings led us to question a mechanistic link between the expression of bcatenin and the expression of RORgt in T cells during colitis and colon cancer (12) .
The biological role of b-catenin activation in T cells was revealed by analysis of mouse models. Previously, we had shown that APC +/D468 mice with hereditary polyposis depend on T H 17 cytokines to develop polyps and, in addition, have a subset of RORgt + T regs with proinflammatory properties (12) . The APC +/D468 model allowed us to examine how expression of RORgt was related to expression of b-catenin. We demonstrated by independent assays that in polyp-ridden APC +/D468 mice, effector T cells and T regs express high levels of b-catenin and Wnt pathway genes. Using the CD4CreCtnnb1 ex3 and Foxp3CreCtnnb1 ex3 models of sustained b-catenin activity, we showed that persistent Wnt/b-catenin signaling in all T cells or only T regs culminated in longlasting colitis, eventually progressing to intestinal and colon adenomatous polyps. We ruled out the possibility that this pathology resulted from leaky expression of stable b-catenin in gut epithelial cells, by showing absence of disease in lymphocytedeficient Rag2 −/− CD4CreCtnnb1 ex3 mice. It is well known that chronic inflammation in the colon predisposes to cancer, and our mouse models provided insight into the mechanistic relevance of b-catenin signaling in T cells to this process. In particular, the mouse model demonstrated that sustained activation of b-catenin in human T cells is biologically relevant. This was further substantiated with the APC +/D468 mouse model of hereditary polyposis. T cells and, in particular, T regs in these mice had similar characteristics to their counterparts in CD4CreCtnnb1 ex3 mice and in colon cancer patients, including overexpression of b-catenin.
Our earlier studies highlighted the strategically important role of T regs in the control of T H 17 inflammation during mouse polyposis (18) and also pointed to a similar function in human colon cancer (12) . We previously showed that T reg -targeted ablation of RORgt protects APC +/D468 mice against polyposis (12) . Here, we demonstrated that T reg -targeted activation of b-catenin increased gut infiltration by lymphocytes and culminated in reactive tissue as well as bona fide adenomatous polyps. These observations agree with the notion that Wnt/b-catenin signaling in T regs is critical for gain of T reg proinflammatory properties and contributes to the carcinogenic processes in the intestine and colon.
Stabilized b-catenin mediates its effects by translocating to the nucleus, where it interacts with DNA binding Tcf/Lef (lymphoid enhancer factor) factors and regulates transcription of target genes. We showed that expression of genes associated with T cell activation and T H 17 lineage commitment is up-regulated after stabilization of b-catenin in CD4CreCtnnb1 ex3 thymocytes. Many of these genes were naturally elevated in gut-infiltrating T cells during polyposis. These global changes in gene expression involved b-catenin-induced changes in chromatin accessibility. ChIPseq of Tcf-1 and chromatin marks revealed that in thymocytes, Tcf-1 binds primarily to its conserved binding motifs in bona fide promoter and enhancer regions of target genes (46) . Activation of b-catenin increased the accessibility of these sites through the deposition of H3KAc marks over long distances from the Tcf-1 binding. Our results are consistent with earlier findings in Drosophila, showing recruitment of b-catenin to TCF DNA binding sites in complex with the histone H3 acetyltransferase (HAT) CBP, and rapid, extensive histone acetylation (47) .
We showed that Tcf-1 binds to consensus motifs in the Rorc locus. Activation of b-catenin enhanced H3KAc in this locus and promoted the expression of RORgt in T cells including T regs . Our findings confirm and extend recent observations that in thymocytes, RORgt gene expression is regulated by Wnt/b-catenin signaling (30) . However, we did not find increased Tcf-1 binding to DNA in response to stabilization of b-catenin; rather, we observed that b-catenin enhances accessibility of the locus. Our findings are consistent with reports that Wnt/b-catenin genes are up-regulated during in vitro T H 17 differentiation of T cells (33) . Our results are also consistent with reports that Tcf-1 suppresses IL-17 gene expression and with the notion that elevated levels of b-catenin convert this suppression to activation (34, 35) . Finally, our results agree with a recent report indicating that T reg differentiation involves the programmed epigenetic closing of sequences with Tcf/Lef binding motifs (48) , and further suggest that elevated levels of b-catenin prevent this process, resulting in T H 17 commitment of thymocytes and defective T reg development.
In summary, we demonstrated that T cells and T regs have tumorpromoting roles in colon cancer that are epigenetically imprinted by Wnt/b-catenin signaling, the same pathway that initiates colon cancer in intestinal epithelial cells. Because b-catenin is also up-regulated in proinflammatory monocytes and antigen-presenting cells (49) , it is an attractive candidate molecule for shaping a tumor-promoting cancer field (50) in inflammation-driven malignancies. One potential caveat is that up-regulation of b-catenin in T cells and T regs may be a common feature of all chronic inflammatory diseases. 
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Detailed Materials and Methods are provided in the Supplementary Materials.
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